Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

By C. Carpenito, M. Milone, R. Hassan, Jacqueline C. Simonet, M. Lakhal, M. Suhoski, Angel Varela‐Rohena, K. Haines, Daniel F. Heitjan, S. Albelda and 4 more. 2009

871 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pulmonary and Respiratory Medicine

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Mesothelin-targeted CAR-T cell therapy for solid tumors (2020, background): “Third-generation CARs consist of two co-stimulatory domains (such as CD28, 4–1BB, OX40, DNAX-activating protein 10 (DAP10), Toll-like receptor-2 (TLR2)) alongside CD3ζ [76,79] (Figure 2).”
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “To provide the costimulation lacking in tumor cell targets and thereby overcome the above limitations, several groups have incorporated costimulatory endodomains, including CD28 (12), 4-1BB (13, 14), or OX40 (15), into CAR molecules (so-called secondgeneration CARs).”
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, neutral): “CRS has been observed to begin earlier when CAR T-cell products with a CD28 costimulatory domain are administered, compared with CAR T-cell products with a 4–1BB costimulatory domain [43], and cell products with a 4–1BB costimulatory domain might have greater persistence [66].”
Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies (2013, positive): “resis to isolate T cells for expansion and electroporation with an antimesothelin ss1 scFv CAR mRNA construct containing the 4-1BB and TCR-z signaling modules, as described previously (15).”
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. (2016, result): “2 × 105 to 3 × 106/kg) were markedly lower than those used in other mesothelioma xenografts studies (41, 42) and are comparable to doses used in current clinical trials for hematologic malignancies (3, 6) and solid tumors (43, 44).”
Cold Tumors: A Therapeutic Challenge for Immunotherapy (2019, background): “CAR T cells responses can be further enhanced by addition of costimulatory domains, such as CD28 and CD137 (4-IBB) to support the expansion and persistence of genetically engineered cells in vivo (91).”
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (2016, positive): “The mesothelin CAR was previously described (Carpenito et al., 2009).”